Join
Live feed
·
PRReleasevia Quantisnow
Rafael Holdings Inc. logo

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

ByQuantisnow·Wall Street's wire, on your screen.
RFL· Rafael Holdings Inc.
Finance

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RFL (Rafael Holdings Inc.) and more on Quantisnow.